论文部分内容阅读
探讨伴脾功能亢进的原发性肝癌治疗。结果表明,A和B两组术中出血及术后并发症的发生率无显著性差异(P>0·05),但术后血小板、白细胞的回升,A组优于B组(P<0·01)。A和B两组1、3和5年的生存率分别为84·12%、50·34%、36·51%及80·50%、31·21%、19·81%,两组3年和5年的生存率统计学有差异性(P<0·01)。肝脾联合切除治疗原发性肝癌没有危险性,是安全有效的治疗措施,可为肝癌的进一步治疗创造了条件。
To investigate the treatment of primary liver cancer with hypersplenism. The results showed that the incidence of intraoperative bleeding and postoperative complications in group A and B had no significant difference (P> 0.05), but the number of platelets and white blood cells rose after operation in group A, which was better than group B (P <0 · 01). The 1,3 and 5-year survival rates of A and B groups were 84.12%, 50.34%, 36.51% and 80.5%, 31.21% and 19.81% respectively, and the two groups of three years And 5-year survival rates were statistically different (P <0.01). Hepatic spleen resection of the treatment of primary liver cancer is not dangerous, is safe and effective treatment measures for the treatment of liver cancer to create the conditions for further treatment.